↓ Skip to main content

Looking forward to new targeted treatments for chronic spontaneous urticaria

Overview of attention for article published in Clinical and Translational Allergy, January 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#2 of 635)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
53 news outlets
blogs
1 blog
twitter
39 tweeters
facebook
11 Facebook pages
wikipedia
1 Wikipedia page
video
1 video uploader

Citations

dimensions_citation
38 Dimensions

Readers on

mendeley
62 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Looking forward to new targeted treatments for chronic spontaneous urticaria
Published in
Clinical and Translational Allergy, January 2017
DOI 10.1186/s13601-016-0139-2
Pubmed ID
Authors

Emek Kocatürk, Marcus Maurer, Martin Metz, Clive Grattan

Abstract

The introduction of omalizumab to the management of chronic spontaneous urticaria (CSU) has markedly improved the therapeutic possibilities for both, patients and physicians dealing with this disabling disease. But there is still a hard core of patients who do not tolerate or benefit from existing therapies and who require effective treatment. Novel approaches include the use of currently available drugs off-licence, investigational drugs currently undergoing clinical trials and exploring the potential for therapies directed at pathophysiological targets in CSU. Off-licence uses of currently available drugs include rituximab and tumour necrosis factor inhibitors. Ligelizumab (anti-IgE), canakinumab (anti-IL-1), AZD1981 (a PGD2 receptor antagonist) and GSK 2646264 (a selective Syk inhibitor) are currently in clinical trials for CSU. Examples of drugs that could target potential pathophysiological targets in CSU include substance P antagonists, designed ankyrin repeat proteins, C5a/C5a receptor inhibitors, anti-IL-4, anti-IL-5 and anti-IL-13 and drugs that target inhibitory mast cell receptors. Other mediators and receptors of likely pathogenic relevance should be explored in skin profiling and functional proof of concept studies. The exploration of novel therapeutic targets for their role and relevance in CSU should help to achieve a better understanding of its etiopathogenesis.

Twitter Demographics

The data shown below were collected from the profiles of 39 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 62 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 21%
Other 8 13%
Student > Ph. D. Student 7 11%
Student > Postgraduate 7 11%
Student > Master 4 6%
Other 9 15%
Unknown 14 23%
Readers by discipline Count As %
Medicine and Dentistry 26 42%
Immunology and Microbiology 5 8%
Agricultural and Biological Sciences 4 6%
Biochemistry, Genetics and Molecular Biology 4 6%
Neuroscience 2 3%
Other 5 8%
Unknown 16 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 454. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 December 2020.
All research outputs
#45,116
of 21,795,229 outputs
Outputs from Clinical and Translational Allergy
#2
of 635 outputs
Outputs of similar age
#1,457
of 423,078 outputs
Outputs of similar age from Clinical and Translational Allergy
#1
of 36 outputs
Altmetric has tracked 21,795,229 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 635 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 423,078 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.